Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is on a quest in the development of healthier nicotine ingestion methods to provide consumers alternatives to lighting up. A recent article discussing the company’s novel drug delivery platform reads, “In a press release from August 2018, Lexaria announced a second-generation study in 40 rats. The study resulted in Lexaria’s formulation being four-times faster at reaching its peak level in brain tissue than the non-enhanced control formulation. In a press release (http://cnw.fm/4SuIM), Chris Bunka, chief executive officer of Lexaria, stated, ‘DehydraTECH delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the need for combustion or the need for inhalation whatsoever. Crossing the blood brain barrier is a significant achievement all on its own and this data confirms the outcome of our earlier first-generation test.’”
To view the full article, visit http://cnw.fm/Jov6X
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000
For more information please visit https://www.CannabisNewsWire.com